Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Puxitatug Samrotecan vs Chemotherapy in Advanced/Metastatic Endometrial Cancer
NCT07044336Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 28
01
Overview
A Phase 3 trial of puxitatug samrotecan in endometrial cancer (EC), sponsored by AstraZeneca. Started Aug 2025; status: recruiting.
02
Drugs
puxitatug samrotecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07044336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044336.